Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group.

N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.

PMID:
25693012
[PubMed - indexed for MEDLINE]
2.

Randomized Phase II-III Study of Bevacizumab in Combination with Chemotherapy in Previously Untreated Extensive Small-Cell Lung Cancer: Results from the IFCT-0802 Trial.

Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, Chatellain P, Barre P, Jeannin G, Mourlanette P, Derollez M, Herman D, Renault A, Dayen C, Lamy PJ, Langlais A, Morin F, Zalcman G; French Cooperative Thoracic Intergroup (IFCT).

Ann Oncol. 2015 Feb 16. pii: mdv065. [Epub ahead of print]

PMID:
25688059
[PubMed - as supplied by publisher]
3.

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.

Couraud S, Souquet PJ, Paris C, Dô P, Doubre H, Pichon E, Dixmier A, Monnet I, Etienne-Mastroianni B, Vincent M, Trédaniel J, Perrichon M, Foucher P, Coudert B, Moro-Sibilot D, Dansin E, Labonne S, Missy P, Morin F, Blanché H, Zalcman G; on behalf of The French Cooperative Intergroup IFCT.

Eur Respir J. 2015 Feb 5. pii: ERJ-00972-2014. [Epub ahead of print]

PMID:
25657019
[PubMed - as supplied by publisher]
4.

Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer.

Humbert O, Cochet A, Coudert B, Berriolo-Riedinger A, Kanoun S, Brunotte F, Fumoleau P.

Oncologist. 2015 Feb;20(2):94-104. Epub 2015 Jan 5. Review.

PMID:
25561512
[PubMed - as supplied by publisher]
5.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A.

Lancet Oncol. 2014 Dec;15(13):1493-502. doi: 10.1016/S1470-2045(14)70475-9. Epub 2014 Oct 30.

PMID:
25456368
[PubMed - in process]
6.

Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer.

Trédan O, Campone M, Jassem J, Vyzula R, Coudert B, Pacilio C, Prausova J, Hardy-Bessard AC, Arance A, Mukhopadhyay P, Aloe A, Roché H.

Clin Breast Cancer. 2015 Feb;15(1):8-15. doi: 10.1016/j.clbc.2014.07.007. Epub 2014 Aug 15.

PMID:
25218708
[PubMed - in process]
7.

Brown adipose tissue activity in relation to weight gain during chemotherapy in breast cancer patients: a pilot study.

Gadea E, Thivat E, Merlin C, Paulon R, Kwiatkowski F, Chadeyras JB, Coudert B, Boirie Y, Morio B, Durando X.

Nutr Cancer. 2014;66(7):1092-6. doi: 10.1080/01635581.2014.948212. Epub 2014 Aug 26.

PMID:
25157743
[PubMed - in process]
8.

Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.

Chevrier S, Arnould L, Ghiringhelli F, Coudert B, Fumoleau P, Boidot R.

Int J Oncol. 2014 Sep;45(3):1167-74. doi: 10.3892/ijo.2014.2528. Epub 2014 Jun 27.

PMID:
24990411
[PubMed - indexed for MEDLINE]
9.

HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.

Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F.

Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1525-33. doi: 10.1007/s00259-014-2739-1. Epub 2014 Mar 20.

PMID:
24647576
[PubMed - indexed for MEDLINE]
10.

¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P, Brunotte F.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):428-37. doi: 10.1007/s00259-013-2595-4. Epub 2013 Nov 7.

PMID:
24196916
[PubMed - indexed for MEDLINE]
11.

Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study.

Baffert S, Cottu P, Kirova YM, Mercier F, Simondi C, Bachelot T, Le Rhun E, Levy C, Gutierrez M, Madranges N, Moldovan C, Coudert B, Spaëth D, Serin D, Cotté FE, Benjamin L, Maillard C, Laulhere-Vigneau S, Durand-Zaleski I.

BMC Health Serv Res. 2013 Oct 31;13:456. doi: 10.1186/1472-6963-13-456.

PMID:
24176086
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

[Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies].

Gadéa É, Thivat É, Wang-Lopez Q, Viala M, Paulon R, Planchat É, Chadeyras JB, Merlin C, Coudert B, Bignon YJ, Morio B, Durando X.

Bull Cancer. 2013 Sep;100(9):865-70. doi: 10.1684/bdc.2013.1802. French.

PMID:
24045219
[PubMed - indexed for MEDLINE]
13.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators.

Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11.

PMID:
23764181
[PubMed - indexed for MEDLINE]
14.

Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy.

Guiu S, Mouret Reynier MA, Toure M, Coudert B.

J Oncol. 2013;2013:854121. doi: 10.1155/2013/854121. Epub 2013 Apr 29.

PMID:
23737784
[PubMed]
Free PMC Article
15.

Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study.

Dabakuyo TS, Arnaud A, Maingon P, Causeret S, Coudert B, Fumoleau P, Arnould L, Poillot ML, Arveux P, Crehange G, Bonnetain F.

Eur J Cancer Care (Engl). 2013 Sep;22(5):638-47. doi: 10.1111/ecc.12069. Epub 2013 May 5.

PMID:
23647444
[PubMed - indexed for MEDLINE]
16.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

PMID:
22982650
[PubMed - indexed for MEDLINE]
17.

Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.

Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, Créhange G, Coutant C, Fumoleau P, Coudert B.

Breast. 2013 Jun;22(3):301-8. doi: 10.1016/j.breast.2012.07.012. Epub 2012 Aug 3.

PMID:
22863283
[PubMed - indexed for MEDLINE]
18.

Microfluidic: an innovative tool for efficient cell sorting.

Autebert J, Coudert B, Bidard FC, Pierga JY, Descroix S, Malaquin L, Viovy JL.

Methods. 2012 Jul;57(3):297-307. doi: 10.1016/j.ymeth.2012.07.002. Epub 2012 Jul 11. Review.

PMID:
22796377
[PubMed - indexed for MEDLINE]
19.

Albumin-coated monodisperse magnetic poly(glycidyl methacrylate) microspheres with immobilized antibodies: application to the capture of epithelial cancer cells.

Horák D, Svobodová Z, Autebert J, Coudert B, Plichta Z, Královec K, Bílková Z, Viovy JL.

J Biomed Mater Res A. 2013 Jan;101(1):23-32. doi: 10.1002/jbm.a.34297. Epub 2012 Jul 6.

PMID:
22767416
[PubMed - indexed for MEDLINE]
20.

Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.

Giacchetti S, Dugué PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R, Tampellini M, Adam R, Moreau T, Lévi F; ARTBC International Chronotherapy Group.

Ann Oncol. 2012 Dec;23(12):3110-6. doi: 10.1093/annonc/mds148. Epub 2012 Jun 27.

PMID:
22745214
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk